Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Work
Year: 2018
Type: article
Abstract: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of bene... more
Source: New England Journal of Medicine
Authors Matthew D. Hellmann, Tudor‐Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson +19 more
Institutions Memorial Sloan Kettering Cancer Center, Institute of Oncology Prof. Dr. Ion Chiricuta, Iuliu Hațieganu University of Medicine and Pharmacy, Centrum Onkologii, Seoul National University Bundang Hospital +15 more
Cites: 20
Cited by: 2,746
Related to: 10
FWCI: 192.3
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funder Bristol-Myers Squibb